David MD's Colleagues at Leading BioSciences, Inc.
David MD's Contact Details
Leading BioSciences, Inc.
David MD's Company Details
Leading BioSciences is developing oral protease inhibitors to improve acute and chronic patient outcomes resulting from gut barrier pathologies. The Company's initial focus is combatting the interruption of GI function (ileus) following major surgery to reduce recovery times and shorten patients' length of stay in the hospital. Additionally, the company believes that its investigational therapies have the potential to prevent the formation of post-operative adhesions (reducing hospital re-admissions and additional surgeries), as well as to address the myriad of health conditions and complications associated with chronic disruption of the intestinal mucosal barrier. LB1148 is a patent-protected formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases that can cause a range of serious complications and organ dysfunction if they escape the GI tract through a compromised mucosal barrier. A Phase 2 trial of patients undergoing major cardiovascular surgery showed that LB1148 as compared to placebo demonstrated an overall decrease in hospital length of stay of 1.1 days, and a decrease of 1.2 days in the intensive care unit (ICU). The study also demonstrated a 30% improvement in return to bowel function (p < 0.001), the most common requirement delaying hospital discharge after abdominal surgery.Most recently, Leading BioSciences is pursuing opportunities for LB1148 to reverse the often-lethal complications of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) resulting from COVID-19 infections.